Stocktoria
CATALYST PHARMACEUTICALS, INC. CPRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-11-08
CATALYST PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M | $140.8M |
| R&D expense | $12.7M | $12.6M | $93.2M | $19.8M | $16.9M |
| SG&A expense | $193.8M | $177.7M | $133.7M | $57.1M | $49.6M |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M | $52.4M |
| Income tax | $69.2M | $52.4M | $23.1M | $21.6M | $13.2M |
| Net income | $214.3M | $163.9M | $71.4M | $83.1M | $39.5M |
| EPS (diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 |
| Operating cash flow | $208.7M | $239.8M | $143.6M | $116.0M | $60.4M |
| Free cash flow | $208.6M | $239.3M | $143.4M | $116.0M | $59.4M |
| Cash & equivalents | $709.2M | $517.6M | $137.6M | $298.4M | $171.4M |
| Inventory | $37.2M | $19.5M | $15.6M | $6.8M | $7.9M |
| Total assets | $1.1B | $851.4M | $470.1M | $375.6M | $237.8M |
| Total liabilities | $149.7M | $123.8M | $82.2M | $75.2M | $31.0M |
| Shareholders' equity | $954.3M | $727.6M | $387.9M | $300.4M | $206.8M |
Source: SEC EDGAR filings · CIK 0001369568 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.